anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: This study aimed to evaluate the effects of acupressure and reflexology on fatigue in chronic lymphocytic leukemia patients.
METHOD: In this randomized controlled trial with three arms and a pretest-posttest design, 102 CLL patients were randomly allocated to acupressure (n = 34), reflexology (n = 34), or control (n = 34) groups. Pre-intervention assessments were conducted using a demographic questionnaire and a fatigue scale for cancer patients. The acupressure group received routine care with acupressure targeting the SP6 point for 10 min twice daily over four weeks. The reflexology group received daily 10-minute reflexology sessions over four consecutive weeks following the preparation and lubrication of the soles of their feet with sweet almond oil. Post-intervention assessments were administered to all groups using the same instruments.
RESULTS: Results showed both acupressure and reflexology significantly reduced fatigue compared to the control group (P < 0.001). While differences were noted between acupressure, reflexology, and control groups initially, the post-intervention analysis revealed no significant variance between acupressure and reflexology in reducing fatigue (P < 0.05), suggesting similar improvement between acupressure and reflexology.
CONCLUSIONS: Acupressure and reflexology are recommended as cost-effective and low risk complementary approaches for managing fatigue in chronic lymphocytic leukemia patients. These therapies offer promise in alleviating fatigue and enhancing the quality of life for cancer patients.
The present invention relates to cosmetic water-in-oil emulsion compositions containing solid particles and high concentrations of a specific silicone elastomer. The present invention deals more specifically with a water-in-oil emulsion comprising high content of polysilicon-11, solid particles providing at least one optical effect, and at least one silicon emulsifier. The emulsions of the invention are suitable for use for making up the face and/or lips or eyelids, preferably as foundations. They may also be used to as a base for make¬ up, or as a skin care cream to be applied on the body or face. These compositions result in a product that enhances the overall appearance of the skin by providing strong blurring effects to give anti-wrinkle/fine line effects, skin smoothness, and radiance while unifying color complexion. These compositions also have unique sensorial properties.
PROBLEM TO BE SOLVED: To specify a method for inducing apoptotic death of a neoplastic cell. SOLUTION: This method for inducing the apoptotic death of the neoplastic cell comprises bringing an apoptosis-inducing amount of a methylol-containing compound into contact with the neoplastic cell. The method is useful for treating both primary cancers and metastatic cancers. A preferred embodiment includes a step of administering a methylol-transfer agent at a total daily dose of about 2 g to about 60 g to mammals. The administration includes at least two dosing cycles and each dosing cycle includes an infusion phase of about 1 to 8 days and a non-administration phase of about 1 to 14 days. Another embodiment includes a step of treating liver cancer by directly administering a solution of the methylol-transfer agent through a hepatic vessel to the liver.
OBJECTIVE: To identify and prioritise early pregnancy risk factors for stillbirth to inform prognostic factor and model research.
STUDY DESIGN: We used a modified e-Delphi method and consultation meeting to achieve consensus. Risk factors for early, late and stillbirth at any gestation identified from an umbrella review of risk factors for stillbirth were entered into a two-stage online Delphi survey with an international group of stakeholders made up of healthcare professionals and researchers. The RAND/ University of California at Los Angeles appropriateness method was used to evaluate consensus. Responders voted on a scale of 1-9 for each risk factor in terms of importance for early, late, and stillbirth at any gestation. Consensus for inclusion was reached if the median score was in the top tertile and at least two thirds of panellists had scored the risk factor within the top tertile.
RESULTS: Twenty-six risk factors were identified from an umbrella review and presented to stakeholders in round 1 of our e-Delphi survey. Round 1 was completed by 68 stakeholders, 79% (54/68) of whom went on to complete the second round. Seventeen risk factors were discussed at the consensus meeting. From the twenty-six risk factors identified, fifteen of these were prioritised for stillbirth at any gestation, eleven for early stillbirth, and sixteen for late stillbirth, across three domains of maternal characteristics, ultrasound markers and biochemical markers. The prioritised maternal characteristics common to early, late, and stillbirth at any gestation were: maternal age, smoking, drug misuse, history of heritable thrombophilia, hypertension, renal disease, diabetes, previous stillbirth and multiple pregnancy. Maternal BMI, access to healthcare, and socioeconomic status were prioritised for late stillbirth and stillbirth at any gestation. Previous pre-eclampsia and previous small for gestational age baby were prioritised for late stillbirth. Of the ultrasound markers, uterine artery Doppler pulsatility index and congenital fetal anomaly were prioritised for all. One biochemical marker, placental growth factor, was prioritised for stillbirth at any gestation.
CONCLUSIONS: Our prioritised risk factors for stillbirth can inform formal factor-outcome evaluation of early pregnancy risk factors to influence public health strategies on prevention of such risk factors to prevent stillbirth.
Group 1 (n= 15): the root canals were instrumented with rotary LightSpeed LSX instruments (Discus Dental, Culver City, CA, USA). They were used to complete the canal preparation to a size #50 for the anteriors and molar teeth to size #40.
Administer placebo for 1 week and study the outcome parameters. After 1 week of washout, administer DA-9701 for 1 week and assess the outcome parameters again.
Devices for fast easy monitoring of analyte levels, disease, or other physiological changes are provided. In some cases, the devices may include particles or the like that can be placed and read at the site of detection, typically on or in the skin or mucosa. In one embodiment, the particles may include anisotropic particles. Typically the devices will typically provide a visual colorimetic signal, but other signals are possible, such as smell, taste (e.g., release of food acceptable flavor), or tactile (e.g., shape change). The devices are preferably single use, disposable devices, although some may be able to provide multiple readings over a period of time. These devices may be used with any patient and are particularly useful for pediatric and elderly patients, as well as for the military, and people without health insurance. The devices can be used to assess when intervention may be required without expensive testing at a physician's office, or simply for routine maintenance of those who are concerned about their health.
BACKGROUND: Acute kidney injury (AKI) is one of the most common complications after living-donor liver transplantation (LDLT) that has great impact on recipient and graft outcomes. Dexmedetomidine is reported to decrease the incidence of AKI. In the current study, the authors investigated whether intraoperative dexmedetomidine infusion would reduce the AKI following LDLT.
MATERIAL AND METHODS: In total, 205 adult patients undergoing elective LDLT were randomly assigned to the dexmedetomidine group ( n =103) or the control group ( n =102). Dexmedetomidine group received continuous dexmedetomidine infusion at a rate of 0.4 mcg/kg/h after the anesthesia induction until 2 h after graft reperfusion. The primary outcome was to compare the incidence of AKI. Secondary outcomes included serial lactate levels during surgery, chronic kidney disease, major adverse cardiovascular events, early allograft dysfunction, graft failure, overall mortality, duration of mechanical ventilation, intensive care unit, and hospital length of stay. Intraoperative hemodynamic parameters were also collected.
RESULTS: Of 205 recipients, 42.4% ( n =87) developed AKI. The incidence of AKI was lower in the dexmedetomidine group (35.0%, n =36/103) compared with the control (50.0%, n =51/102) ( P =0.042). There were significantly lower lactate levels in the dexmedetomidine group after reperfusion [4.39 (3.99-4.8) vs 5.02 (4.62-5.42), P =0.031] until the end of surgery [4.23 (3.73-4.74) vs 5.35 (4.84-5.85), P =0.002]. There were no significant differences in the other secondary outcomes besides lactate. Also, intraoperative mean blood pressure, cardiac output, and systemic vascular resistance did not show any difference.
CONCLUSION: Our study suggests that intraoperative dexmedetomidine administration was associated with significantly decreased AKI incidence and lower intraoperative serum lactate levels in LDLT recipients, without untoward hemodynamic effects.
Administer PROAIR RESPICLICK by oral inhalation only. PROAIR RESPICLICK inhaler does not require priming. Do not use PROAIR RESPICLICK with a spacer or volume holding chamber.

Keep the inhaler clean and dry at all times. Never wash or put any part of your inhaler in water. Routine maintenance is not required. If the mouthpiece needs cleaning, gently wipe the mouthpiece with a dry cloth or tissue as needed.
The invention relates to the field of medicine and, in particular, to the development of pharmaceutical compositions containing protein NMA0939. The inventive proteins provide protection against different diseases which may or may not be caused by pathogens. Protein NMA0939 was identified as a component of preparations of outer membrane vesicles of Neisseria meningitidis and was obtained using recombinant DNA technology. The immunogenicity and protective activity thereof was evaluated in animal models. Owing to the high level of conservation of the gene that codes for protein NMA0939, the compositions that contain same are of high value as an antigen that can induce an immune response with broad reactivity. The inventive compositions are suitable for use in human medicine.
FIELD: biotechnology, virology, vaccines. SUBSTANCE: invention describes 12 peptide- simulators of human immunodeficiency type-1 virus protein gp41 conservative epitope prepared by affinity selection from phage peptide libraries. These peptides differ from HIV-1 protein gp41 conservative epitope by amino acid sequence but retain ability to bind with virus-neutralizing monoclonal antibodies 2F5. Invention ensures to obtain high-effective vaccine against HIV based on peptides indicated. Invention can be used in development of effective vaccine preparations against AIDS. EFFECT: enhanced effectiveness of vaccine, valuable medicinal properties. 12 cl, 3 dwg, 2 ex
This article reports the development of a new self-powered smart electrocardiogram (ECG) monitoring system, consisting of the related hardware, firmware, and Internet of Things (IoT)-based web service for artificial intelligence (AI)-assisted arrhythmia detection and a complementary Android application for data streaming The hardware aspect of this article proposes an ultralow power patch sampling ECG data at 256 samples/s with 16-bit resolution. The battery life of the device is two weeks per charging, which alongside the flexible and slim (193.7 mm ×62.4 mm ×8.6 mm) and lightweight (43 g) allows the user to continue real-life activities while the real- time monitoring is being done without interruption. The power management is achieved through the usage of switching converters, ultralow power component choice, as well as intermittent usage of them through firmware optimization. A novel data encoding method is also proposed to allow the compression of data and lower the runtime. The software aspect, in addition to the web ECG analysis platform and the Android streaming and monitoring application, provides an arrhythmia detection service. The key innovations in this regard are the usage of a set of new factors in determining arrhythmia that grants higher accuracy while retaining the detection near-real-time. The arrhythmia detection algorithm shows 98.7% accuracy using artificial neural network and K-nearest neighbors methods and 98.1% using decision tree method on test dataset. The system incorporates a groundbreaking thermoelectric self-powering mechanism, leveraging body heat to autonomously power the ECG patch, enhancing its efficiency and independence in wearable healthcare technology
N-acetylcysteine (NAC) is a commonly used mucolytic agent and antidote for acetaminophen overdose. For pulmonary diseases, NAC exhibits antioxidative properties, regulates cytokine production, reduces apoptosis of lung epithelial cells, and facilitates the resolution of inflammation. However, the efficacy of NAC in clinical trials targeting different pathological conditions is constrained by its short half-life and low bioavailability. In the present study, a series of NAC derivatives were designed and synthesized to further enhance its pharmacological activity. Structure-activity relationship (SAR) studies were conducted to optimize the activating groups. In vitro evaluations revealed that compounds 4 r, 4 t, 4 w, and 4 x exhibited superior antioxidative and anti-inflammatory activities compared to the positive controls of NAC and fudosteine. The ADME prediction analysis indicated that these compounds exhibited a favorable pharmacological profile. In-vivo experiments with compound 4 r demonstrated that the high-dose group (80 mg/kg) exhibited improved therapeutic effects in reversing the HPY level in mice with pulmonary fibrosis compared to the NAC group (500 mg/kg), further proving its superior oral bioavailability and therapeutic effect compared to NAC.
A transgenic, non-human mammal useful for assessing the effect of candidate chemotherapeutic drugs on the growth of brain tumors in vivo is provided. Incorporated into the genome of the transgenic mammal, which preferably is a rodent, is a transgene which comprises a promoter comprising the nuclear factor binding region of the RR2 cis acting element of a fibroblast growth factor 1B (FGF1B) promoter. Operably linked to the promoter is reporter gene comprising a sequence which encodes the SV40 large T antigen. A transgenic, non-human mammal useful for identifying and isolating FGF1 producing brain cells. Incorporated into the genome of these transgenic animals is a transgene which comprises a promoter comprising the nuclear factor binding region of the RR2 cis acting element of an fibroblast growth factor 1B (FGF1B) promoter. Operably linked to the promoter is reporter gene comprising a sequence which encodes a protein or polypeptide other than an SV40 large T antigen. A method of obtaining neural stem cells from a sample of cells obtained from an animal is also provided. Such method comprises introducing the FGF1B-detector transgene into a sample of cells that have been obtained from the animal, and assaying for expression of the detectable marker in the cells, wherein cells that express the marker are neural stem cells. The cells which express the detectable marker can then be isolated from the population to provide a sub-population of neural stem cells.
BACKGROUND: Urinary incontinence (UI) is a common condition in female. Oxidative stress and inflammation levels play important roles in UI progression. Mediterranean diet (MD) as a healthy anti-inflammatory dietary pattern has been reported to be associated with several inflammatory diseases. This study aimed to assess the association between the adherence to Mediterranean diet (aMED) and female UI.
METHODS: Data of study women aged ≥18 years old and diagnosed as stress UI and urgency UI were extracted from the National Health and Nutrition Examination Survey (NHANES) 2005-2018. Dietary intake information was obtained by 24-h dietary recall interview. Covariates included sociodemographic information, physical examination, and history of diseases and medication were extracted from the database. The weighted univariable and multivariate logistic regression models were used to assess the association between aMED and different types of UI, with odds ratios (ORs) and 95% confidence intervals (CIs). Subgroup analysis were further evaluated this association based on different age, body mass index (BMI), neutrophil to lymphocyte ratio (NLR), depression and smoking.
RESULTS: Totally, 13,291 women were included, of whom 5,921 (44.55%) had stress UI, 4276 (32.17%) had urgency UI and 2570 (19.34%) had mixed UI. After adjusted all covariates, high aMED score was associated with the lower odds of urgency (OR = 0.86, 95%CI: 0.75-0.98) and mixed UI (OR = 0.84, 95%CI: 0.70-0.99), especially in female, aged 45-60 years old, NLR ≥1.68 and had smoking history. No relationship was found between the aMED and stress UI (P >0.05).
CONCLUSION: Greater aMED was connected with the low odds of urgency UI and mixed UI among female. Adherence to an anti-inflammatory diet in daily life are a promising intervention to be further explored in female UI.
The experimental group is the group that received yoga. The individuals originally assigned to the WLC who completed the yoga intervention AFTER the 8 weeks WLC period also are considered part of the experimental group.
Subjects randomized to the (Delay CNI) group will be treated with Thymoglobulin® (total dose of 4.5 mg/kg) administered in three doses; (each dose being 1.5 mg/kg - administered Day 0 \[after transplant\], Day 2, and Day 4 post transplant), along with CNI delay for 10 days. CNI will be initiated on postoperative (post-transplant) Day 10. Subjects will also receive a maintenance immunosuppression regimen of corticosteroids and MMF in accordance with the standard practice at each clinical center.
Experiment 1 will involve N= 14 subjects randomized to placebo , 10 mg zolpidem for males and 10 mg zaleplon in counterbalanced order. Subjects are nested into group.
The invention belongs to the field of Chinese medicines and relates to a quick healing spray for burn and a preparation technique thereof. The quick healing spray is essentially composed of 80-105 parts of garden burnet, 40-75 parts of euphorbia humifusa, 20-25 parts of common cissampelos herb, 20-25 parts of calcined oyster, 10-15 parts of calcined plaster and 10-15 parts of cutch. The quick healing spray has the efficacies of clearing away heat and toxic materials, dispelling heat from blood to stop bleeding, resisting bacteria, diminishing inflammation, calming, alleviating pains, promoting granulation and astringing wounds. The quick healing spray can be applied to the treatment of large-area and deep burns and scalds caused by various physical and chemical factors through external application, and can be used for treating scorch and injuries on the respiratory tract and the esophagus through oral administration. Furthermore, the quick healing spray can effectively eliminate thermotoxin, prevent body fluid from leaking out, facilitate quick escharosis, avoid infection, eliminate scar and restore sweat glands. Moreover, the quick healing spray of the invention is not restricted by environmental conditions and has significant advantages for clinical treatment, field first aid of the industries like iron and steel, smelting, chemical engineering, thermal electricity, heating industry, fire fighting, field working as well as the field first aid for the burns and wounds caused by various natural disasters and wartime or unexpected group injuries.
Patients awaiting for surgical procedure for a symptomatic pelvic organ prolapse (POP) are recruited for the study. The recruiting is done in 41 hospitals in Finland, at gynecological outpatient clinics. Participants are given information of the study and give a written approval to join the study. Participants are asked to fill in questionnaires, that measure the quality of life. Three validated questionnaires are used: Pelvic Floor Distress Inventory PFDI-20, Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire PISQ-12 and health-related quality of life instrument 15D. These questionnaires are sent to participants 6 months, 2 and 5 years after the surgical treatment. The participants are also asked to report adverse effects related to the treatment and their satisfaction to the treatment. Information about the surgical procedure (i.e. type and duration of the procedure, blood loss, antibiotic and thrombosis prophylaxis) by the operating doctors. Both immediate and delayed treatment-related adverse effects are also reported by the doctors. Data is partly collected by questionnaires filled in internet. All the collected data is protected by high security and coded before analyses. Permission of protocol used in this study is given by the Ethical Committee of University of Eastern Finland and Finnish National Institute for Health and Welfare.
Relating to the field of medicine, the invention in particular provides a blood lipid lowering Chinese medicinal composition, a preparation and a preparation technology thereof. The Chinese medicinal composition provided by the invention comprises, by weight part, 133-174 of Salvia Miltiorrhiza, 67-87 of Radix Paeoniae Rubra, 17-22 of hawthorn, 400-733 of ginkgo leaf, and 24-54 of Panax notoginseng. The invention also provides an effervescent tablet preparation containing the Chinese medicinal composition. The Chinese medicinal composition provided by the invention has significant blood lipid lowering effect, is especially suitable for high blood lipid patients. And the effervescent tablet has the characteristics of rapid disintegration, good taste, easy carrying, and convenient use. Also, the preparation process has the advantages of simplicity, convenient operation, good compressibility, and continuous tabletting without sticking and picking.
The invention provides Chinese medicinal formulae for treating cerebral apoplexy and a method of application thereof. Based on the degrees and clinical manifestations of cerebral apoplexy, the Chinese medicinal formulae are applied externally on head respectively by suiting the medicine to the illness, specifically, a Huoxue musk liquid is adopted for patients with meridian cerebral ischemia, a Tianma gouteng drink is adopted for patients with meridian multiple cerebral infarction accompanied with acroparalysis, a Tianma zhibao liquid is adopted for patients with Zang-Fu blockage syndrome, a Renshen huiyang liquid is adopted for patients with Zang-Fu prostration syndrome, or a Xionghuang zhitan powder is simultaneously adopted for external application on foot bottom. The Chinese medicinal formulae are applied for 24 hours and changed once per day, and one course of treatment lasts for 7 days. With the Chinese medicinal formulae for treating cerebral apoplexy, head treatment and foot bottom treatment are combined, primary lesion can be treated at the early stage of occurrence of disease and the sequela of acroparalysis is treated with quick effect without any toxic side effects. Shown by statistical results, the treatment group has an obvious effect on reducing the disability rate and death rate of patients, the effective rate is 91%, and the obvious effective rate is 62%. The Chinese medicinal formulae for treating cerebral apoplexy also have notable curative effects on nerve headache, refractory insomnia, neurosis and the like.